PRATEEK RAI

Mr. PRATEEK RAI

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Synthetic Communications
Verified
Journal Article
Closed access
PRPRATEEK RAI
PRATEEK RAI
DGDeepshikha Gupta
Deepshikha Gupta
In the last few decades in chemical science have seen efforts being made to make the process of chemical synthesis greener. The green chemistry principles demand a catalytic system that not only transforms the reacting species into profitable chemicals, pharmaceuticals, fuels, etc. at an accelerated rate but also tends to reduce the generation of waste, increase atom economy having a facile separation procedure. Nanocatalysis provides one of the paths to ensure the amplified efficacy of the catalytic process by acting as a bridge between the Homogeneous and Heterogeneous catalysts. The issue of the cumbersome separation process of isolating the nanocatalyst from the reaction medium is resolved by using magnetically separable nanoparticles-based catalysts. This review discusses the significance of magnetic nanocatalysis and its utilization in various prominent chemical transformations in organic syntheses such as hydrogenation reactions, oxidation reactions, carbon-carbon coupling reactions, click reactions, synthesis involving organocatalysis, and other miscellaneous reactions. Graphical Abstract

21 January 2022 in Trends in Environmental Analytical Chemistry
Verified
Journal Article
Closed access
SCShashi Chawla
Shashi Chawla
PRPRATEEK RAI
PRATEEK RAI
TGTanya Garain
Tanya Garain
SUS. Uday
S. Uday
Chaudhery Mustansar HussainChaudhery Mustansar Hussain
Chaudhery Mustansar Hussain

4 September 2025 in Sensors
Verified
Journal Article
Open access
PDF file
SFSayo Fakayode
Sayo Fakayode
DBDavid Bwambok
David Bwambok
SBSouvik Banerjee
Souvik Banerjee
PRPRATEEK RAI
PRATEEK RAI
RORonald Okoth
Ronald Okoth
UBUfuoma Benjamin
Ufuoma Benjamin
Nitrosamines, including N-nitroso diethylamine (NDEA) have emerged as pharmaceutical impurities and carcinogenic environmental contaminants of grave public health safety concerns. This study reports on the preparation and first use of cysteine–gold nanoparticles (CysAuNPs) for colorimetric detection of NDEA in human serum albumin (HSA) under physiological conditions. Molecular docking (MD) and molecular dynamic simulation (MDS) were performed to probe the interaction between NDEA and serum albumin. UV–visible absorption and fluorescence spectroscopy, dynamic light scattering (DLS), and transmission electron microscopy (TEM) imaging were used to characterize the synthesized CysAuNPs. These CysAuNPs show a UV–visible absorbance wavelength maxima (λmax) at 377 nm and emission λmax at 623 nm. Results from DLS measurement revealed the CysAuNPs’ uniform size distribution and high polydispersity index of 0.8. Microscopic imaging using TEM showed that CysAuNPs have spherical to nanoplate-like morphology. The addition of NDEA to HSA in the presence of CysAuNPs resulted in a remarkable increase in the absorbance of human serum albumin. The interaction of NDEA–CysAuNPs–HSA is plausibly facilitated by hydrogen bonding, sulfur linkages, or by Cys–NDEA-induced electrostatic and van der Waal interactions. These are due to the disruption of the disulfide bond linkage in Cys–Cys upon the addition of NDEA, causing the unfolding of the serum albumin and the dispersion of CysAuNPs. The combined use of molecular dynamic simulation and colorimetric experiment provided complementary data that allows robust analysis of NDEA in serum samples. In addition, the low cost of the UV–visible spectrophotometer and the easy preparation and optical sensitivity of CysAuNPs sensors are desirable, allowing the low detection limit of the CysAuNPs sensors, which are capable of detecting as little as 0.35 µM NDEA in serum albumin samples, making the protocol an attractive sensor for rapid detection of nitrosamines in biological samples.

16 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TGTanya Garain
Tanya Garain
PRPRATEEK RAI
PRATEEK RAI
Wei LiWei Li
Wei Li
SBSouvik Banerjee
Souvik Banerjee
ATPase family AAA domain-containing protein 2 (ATAD2) has been recognized as a key oncogene that regulates chromatin remodeling, transcription, and cancer progression. As a member of the bromodomain (BRD) family, ATAD2 plays a crucial role in epigenetic modifications and is associated with multiple malignancies. Despite being considered an undruggable target in the past, crystallography and computational modeling have significantly accelerated ATAD2 drug discovery and development. This review provides a comprehensive overview of the structural features, functional roles, and biological significance of ATAD2, particularly in the context of cancer. We present an in-depth overview of different molecular strategies reported in the literature to suppress ATAD2 expression, including genetic and pharmacological approaches, and discuss their mechanistic and therapeutic implications. Particular emphasis is given to recent efforts in developing small-molecule inhibitors, detailing their binding interactions, therapeutic potential, and challenges in clinical translation. In addition, we performed alanine scanning calculations on molecular dynamics (MD)-simulated trajectories derived from protein–ligand complexes based on X-ray co-crystal structures containing three distinct ligands with different binding modes. This analysis provided critical insights into the binding interface of BRD-ATAD2, enhancing our understanding of its ligand interactions. Furthermore, we examine the emerging roles of ATAD2 in mediating resistance to cancer therapies, underscoring its potential as a target for overcoming drug resistance. By integrating structural insights, mechanistic studies, drug discovery efforts, and the challenges of developing ATAD2-targeted cancer therapies, this review emphasizes the need for further research to optimize ATAD2 inhibition strategies and explore its full therapeutic potential in oncology.

23 July 2021
Verified
Book Chapter
Closed access
PDF file
SCShashi Chawla
Shashi Chawla
DTDivyanshi Thakkar
Divyanshi Thakkar
PRPRATEEK RAI
PRATEEK RAI

27 January 2023
Verified
Book Chapter
Closed access
SCShashi Chawla
Shashi Chawla
IBIshita Bansal
Ishita Bansal
PRPRATEEK RAI
PRATEEK RAI